People · Operator
Named in public records as an officer, director or promoter · active 2014–2024 · Pharmaceuticals, Other
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| CutisPharma, Inc. | — | Pharmaceuticals | Series B | $20.0M | $680.1M | 2014 |
| NanoImaging Services, Inc. | — | Other | Series A | $18.2M | $52.7M | 2023 |
David J. Parker at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside David J. Parker on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Neal Muni | 1 | 2 |
| John Rigg | 1 | 1 |
| Per J. Lofberg | 1 | 1 |
| Arya J. Mehrzbanzad | 1 | 1 |
| Janine H. LeBlanc | 1 | 1 |
| Peter H. Glick | 1 | 1 |
| Per S. Lofberg | 1 | 1 |
| Brian Conkle | 1 | 1 |
| Jens S. Greiser | 1 | 1 |
| Robert S. Curtin | 1 | 1 |
| Clinton S. Potter | 1 | 1 |
| Bridget S. Carragher | 1 | 1 |
| Indu Muni | 1 | 1 |
| Peter Mione | 1 | 1 |
| Bridget H. Carragher | 1 | 1 |
| Eric B Lev | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.